https://informatiestandaarden.nictiz.nl/index.php?action=history&feed=atom&title=mp%3AV3.0.0_Ontwerp_medicatieproces_9_ENG%2Ftabel_klinische_ATC_codes 2026-07-19T16:01:14Z Bewerkingsoverzicht voor deze pagina op de wiki MediaWiki 1.31.16 https://informatiestandaarden.nictiz.nl/index.php?title=mp:V3.0.0_Ontwerp_medicatieproces_9_ENG/tabel_klinische_ATC_codes&diff=299305&oldid=prev 2026-03-23T10:29:10Z

<p>Nieuwe pagina aangemaakt met &#039;{{DISPLAYTITLE: Table with example of clinically relevant medication for extramural health professionals}} <a href="/wiki/mp:V3.0.0_Ontwerp_medicatieproces_9_ENG" class="mw-redirect" title="mp:V3.0.0 Ontwerp medicatieproces 9 ENG">back to FD</a> [...&#039;</p> <p><b>Nieuwe pagina</b></p><div>{{DISPLAYTITLE: Table with example of clinically relevant medication for extramural health professionals}}<br /> [[mp:V3.0.0_Ontwerp_medicatieproces_9_ENG|back to FD]]<br /> <br /> [[mp:V3.0.0_Ontwerp_medicatieproces_9_ENG/aanvullende_documentatie|back to page with additional documentation]]<br /> <br /> {{#lst:mp:V3.0.0_Ontwerp_medicatieproces_9_ENG|informatieoverdracht klinische situatie}}<br /> The table below contains a list of examples of medicinal product groups that may be clinically relevant for extramural healthcare providers.<br /> {| class=&quot;wikitable&quot; &quot;cellpadding=&quot;10&quot;<br /> ! style=&quot;text-align:left;&quot;| ATC group code<br /> ! style=&quot;text-align:left;&quot;| Name<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|L01<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|Cytostatics<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;| L03AX03 <br /> | style=&quot;background-color: white;vertical-align:top;&quot;|BCG vaccine urology<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|L04AA23; L04AA25; L04AA26; L04AA33; L04AA34; L04AB; L04AC <br /> | style=&quot;background-color: white;vertical-align:top;&quot;|Immunosuppressants <br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|B03AC; B03XA; B06AC<br /> | style=&quot;background-color: white;vertical-align:top;&quot;| Iron, epo, agents against angioedema<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|G03GA; G03GB02<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|Gonadotropins (HCG etc), clomiphene<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|H01CA; H01CC; L02AE04 <br /> | style=&quot;background-color: white;vertical-align:top;&quot;|Gonadorelin, hypothalamic hormones, triptorelin<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|J06; J07 <br /> | style=&quot;background-color: white;vertical-align:top;&quot;|Immunoglobulins, vaccines<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|M03AX01<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|Botox<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|R03DX05<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|Omalizumab<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;|S01LA04; S01LA05; S01LA <br /> | style=&quot;background-color: white;vertical-align:top;&quot;|Ophthalmic anti-neovascular agents<br /> |}<br /> <br /> ==Document history==<br /> {| class=&quot;wikitable&quot; &quot;cellpadding=&quot;10&quot;<br /> !style=&quot;text-align:left;&quot;|Version<br /> !style=&quot;text-align:left;&quot;|Date<br /> !style=&quot;text-align:left;&quot;|Description<br /> |-<br /> | style=&quot;background-color: white;vertical-align:top;&quot;| 9 3.0.0-rc.2<br /> | style=&quot;background-color: white;vertical-align:top;&quot;| March 2026<br /> | style=&quot;background-color: white;vertical-align:top;&quot;| for all changes see: *[https://informatiestandaarden.nictiz.nl/wiki/mp:v3.0.0-rc.2_releasenotes_ENG Releasenotes]<br /> |}</div>

Paul Berendsen